VKTX Viking Therapeutics Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
15:36
11 авг
11 авг
Short-term hold on bullish chart setup
Author holds VKTX as a short-term trade citing favorable chart setup; technical observation only, no fundamental catalyst stated.
Низ.
18:40
12 июл
12 июл
Named in a health sector thematic basket the author describes as areas of value they are.
Named in a health sector thematic basket the author describes as areas of value they are rotating across.
Сред.
13:00
30 июн
30 июн
Author names VKTX as a medium-term favorite pick when asked to choose among a group of five.
Author names VKTX as a medium-term favorite pick when asked to choose among a group of five names; low-conviction bullish candidate with no explicit catalyst stated.
Сред.
11:56
30 июн
30 июн
Speaker presents this as a top pick with bullish catalysts (oral Phase 3, chart breakout.
Speaker presents this as a top pick with bullish catalysts (oral Phase 3, chart breakout, target 120), no personal position stated.
Сред.
10:27
29 июн
29 июн
Author expresses love for ABCL and VKTX with bullish commentary on potential and chart.
Author expresses love for ABCL and VKTX with bullish commentary on potential and chart, but no explicit position language or forward call, so both are watch.
Низ.
14:40
27 июн
27 июн
Listed as part of thematic sector overview in author's market read.
Listed as part of thematic sector overview in author's market read, no directional view expressed.
Низ.
00:38
21 июн
21 июн
Автор спрашивает, изучал ли получатель VKTX или ABCL — это исследовательский запрос.
Автор спрашивает, изучал ли получатель VKTX или ABCL — это исследовательский запрос, не содержащий направленной позиции или рекомендации.
Низ.
00:20
20 июн
20 июн
Небольшая спекулятивная корзина «недооцененных активов».
Небольшая спекулятивная корзина «недооцененных активов», удерживаемая в рамках распределения ~5% на криптовалюты/прочие инструменты; автор характеризует их как недооцененные, но не приводит никаких конкретных катализаторов, кроме общего восстановления настроений.
Сред.
09:04
10 июн
10 июн
The author presents a large diversified basket of favorite names across sectors as where they.
The author presents a large diversified basket of favorite names across sectors as where they are positioned for the next few years, but the 30+ tickers default to watch due to the basket size rule.
17:37
09 июн
09 июн
Author discloses current positioning in VKTX as a Health name.
Author discloses current positioning in VKTX as a Health name, framing the dip as a buying opportunity with a multi-year hold thesis.
Сред.
08:37
08 июн
08 июн
Author provides a broad thematic basket of strong buy and buy ratings.
Author provides a broad thematic basket of strong buy and buy ratings with enablers/beneficiaries framing, explicitly recommends selling Carvana, but the large list defaults to watch except for the explicit sell call on CVNA.
Низ.
23:13
05 июн
05 июн
Author lists VKTX in a health/biotech basket with a blanket current-holdings disclosure.
Author lists VKTX in a health/biotech basket with a blanket current-holdings disclosure; thematic basket per speaker note, no ticker-specific thesis.
Низ.
22:27
02 июн
02 июн
Author clarifies that despite past bearishness, their recent positions in Viking Therapeutics.
Author clarifies that despite past bearishness, their recent positions in Viking Therapeutics have been long, defending themselves against being labeled a permabear.
04:37
26 мая
26 мая
Buy VKTX as part of an active short-term trade portfolio.
Buy VKTX as part of an active short-term trade portfolio; author sets explicit upside price target of $35, indicating a committed long position with defined exit.
Сред.
13:09
27 апр
27 апр
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX.
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.
Выс.
22:11
26 апр
26 апр
Explicit portfolio list: 'If I had to hold 10 stocks for 2026'.
Explicit portfolio list: 'If I had to hold 10 stocks for 2026' — first-person commitment to holding $VKTX.
Сред.
15:08
21 апр
21 апр
Speaker found niche peptide stock $VKTX with detailed thesis.
Speaker found niche peptide stock $VKTX with detailed thesis: dual GLP-1/GIP agonist (sub+oral) attacking $100B+ obesity market, both VANQUISH-1 and VANQUISH-2 Phase 3 trials fully enrolled.
Сред.
08:54
20 авг
20 авг
Notes analysts view recent sell-off as exaggerated.
Notes that 10 out of 11 analysts believe the recent sell-off is exaggerated and the underlying data is good.
Сред.
14:46
19 авг
19 авг
Advises against investing in pre-commercial biotech.
Author strongly advises against investing in pre-commercial biotech, comparing the risk to gambling at a casino.
Сред.
08:34
19 авг
19 авг
Speculates on potential acquisition by NVO.
Speculates an acquisition by NVO would make sense given the economic advantages of small molecule GLP1s.
Низ.
20:52
18 дек
18 дек
Long VKTX for best-in-class market candidates
Author discloses a long position in VKTX at $38, arguing its best-in-class candidates for a $130bn market justify a higher valuation.
Выс.
17:36
26 авг
26 авг
Author discloses existing VKTX long position
Author discloses an existing position in VKTX while expressing caution regarding overly bullish retail sentiment.
Сред.
14:28
14 июн
14 июн
Observes post-approval biotech price drops awaiting buyouts.
Observes pattern of biotech stocks dropping to 200-day moving average post-approval while investors await buyouts.
Сред.
16:42
05 июн
05 июн
Notes extreme price volatility despite strong data.
Observes extreme price volatility in VKTX despite consistently strong data, noting market irrationality.
Низ.
13:25
04 июн
04 июн
High buyout probability for best-in-class obesity therapy.
Expects a high probability of a buyout for VKTX, driven by its best-in-class obesity and NASH clinical trials and the massive sales potential in the GLP-1 market.
Выс.
18:08
15 мар
15 мар
VKTX is too risky at current levels
Argues VKTX is too risky with a high probability of failure, suggesting investors are blinded by the GLP-1 total addressable market.
Сред.
Об аналитическом покрытии VKTX
Buzzberg отслеживает VKTX (Viking Therapeutics) в 3 источниках. Бычьих сигналов: 9, медвежьих: 0, от 3 аналитиков. Сентимент преимущественно бычий (35%). Всего отслеживается 26 торговых идей. Последние спикеры: __con_, A May MD, moodywriter13.